Serological identification of human tumor antigens

Current Opinion in Immunology

Volumn 9, Issue 5, 1997, Pages 709-716

  Sahin, Ugur ^a   Türeci, Özlem ^a   Pfreundschuh, Michael ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; T LYMPHOCYTE ANTIGEN; TUMOR ANTIGEN;

REVIEW; SEROLOGY; T LYMPHOCYTE; TUMOR IMMUNITY;

EID: 0342940792     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(97)80053-2     Document Type: Article

References (83)

1. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, van den Eynde, Knuth A, Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 254:1991;1643-1647.
2. Boon T, Cerottini JC, van den Eynde B, van der Bruggen P, van Pel A. Tumor antigens recognized by T-lymphocytes. Annu Rev Immunol. 12:1994;337-366.
3. Rosenberg SA. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today. 18:1997;175-182.
4. Srivastava PK. Do human cancers express shared protective antigens? Or the necessity of remembrance of things past. of special interest Semin Immunol. 8:1996;295-302 Attention is drawn to the fact that for the identification of tumor antigens rejection assays are used in animal models, whereas in vitro generated cytotoxic T lymphocytes have been used as the probes for the identification of shared tumor antigens in humans. The controversy between the finding of unique antigens in animal models and shared antigens in humans by these methods is discussed.
5. Shiku H, Takahashi T, Oettgen HF, Old LJ. Cell surface antigens of human malignant melanoma. II. Serological typing with immune adherence assays and definition of two new surface antigens. J Exp Med. 144:1976;873-881.
6. Pfreundschuh M, Shiku H, Takahashi T, Ueda R, Ransohoff J, Oettgen HF, Old LJ. Serological analysis of cell surface antigens of malignant human brain tumors. Proc Natl Acad Sci USA. 75:1978;5122-5126.
7. Ueda R, Shiku H, Pfreundschuh M, Takahashi T, Whitmore WF, Oettgen HF, Old LJ. Cell surface antigens of human renal cancer defined by autologous typing. J Exp Med. 150:1979;564-579.
8. Old LJ. Cancer Immunology: the search for specificity - G.H.A. Lowes Memorial lecture. Cancer Res. 41:1981;361-375.
9. Neville AM. Detection of tumor antigens with monoclonal antibodies: Immunopathology and immunodiagnosis. Curr Opin Immunol. 3:1991;674-678.
10. Vijayasaradhi S, Bouchard B, Houghton AN. The melanoma antigen gp75 is the human homolog of the mouse b (brown) locus gene product. J Exp Med. 171:1990;1375-1380.
11. Wang RF, Robbins PF, Kawakami Y, Kang XQ, Rosenberg SA. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor infiltrating lymphocytes. J Exp Med. 181:1995;799-804.
12. Adema GJ, de Boer AJ, Vogel AM, Loenen WA, Figdor CG. Molecular characterization of the melanocyte lineage specific antigen gp100. J Biol Chem. 269:1994;20126-20133.
13. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakaguchi K, Appella E, Vannelli JR, Miki T, Rosenberg SA. Identification of a human melanoma antigen recognized by tumor infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA. 91:1994;6458-6462.
14. Kwon BS, Haq AK, Pomerantz SH, Halaban R. Isolation and sequence of a cDNA clone for human tyrosinase that maps at the mouse c-albino locus. Proc Natl Acad Sci USA. 85:1988;6352-6359.
15. Brichard V, Van Pel A, Wölfel C, De Plaen E, Lethe B, Coulie P, Boon T. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med. 178:1993;489-495.
16. Bilbe G, Delabie J, Bruggen J, Richener H, Asselbergs FA, Cerletti N, Sorg C, Odink K, Tarcsay L, Weisendanger W. Restin: a novel intermediate filament-associated protein highly expressed in the Reed-Sternberg cells of Hodgkin's disease. EMBO J. 11:1992;2103-2113.
17. Sahin U, Türeci Ö, Schmitt H, Cochlovius B, Johannes T, Schmits R, Stenner F, Luo G, Schobert I, Pfreundschuh M. Human neoplasms elicit multiple immune responses in the autologous host. Proc Natl Acad Sci USA. 92:1995;11810-11813.
18. Pupa SM, Menard S, Andreola S, Colnaghi M. Antibody response against c-erbB-2 oncoprotein in breast carcinoma patients. Cancer Res. 53:1993;5864-5866.
19. Disis ML, Calenoff E, McLaughlin G, Murphy AE, Chen W, Groner B, Peschke M, Lydon N, McGlynn E, Livingston RB, Cheever MA. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res. 54:1993;16-20.
20. Linzer D, Levine A. Characterization of a 54 Kdalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell. 17:1979;43-52.
21. Crawford LV, Kim DC, Bulbrook RD. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer. 30:1982;403-408.
22. Canevari S, Pupa SM, Menard S. 1975-1995 revised anti-cancer serological response: biological significance and clinical implications. Ann Oncol. 7:1996;227-232.
23. Galloway DA, Jenison SA. Characterization of the humoral immune response to genital papillomaviruses. Mol Biol Med. 7:1990;59-72.
24. Ben-Mahrez K, Sorokine I, Thierry D, Kawasumi T, Ishii S, Salmon R, Kohiyama M. Circulating antibodies against c-myc oncogene product in sera of colorectal cancer patients. Int J Cancer. 46:1990;35-38.
25. Sorokine I, Ben Mahrez K, Bracone A, Thierry D, Ishii S, Imamoto F, Kohiyama M. Presence of ciculating anti c-myb oncogene product antibodies in human sera. Int J Cancer. 47:1991;665-669.
26. Kotera Y, Fontenot JD, Pecher G, Metzgar RS, Finn OJ. Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancretic and colon cancer patients. Cancer Res. 54:1994;2856-2860.
27. Türeci Ö, Sahin U, Pfreundschuh M. Serological analysis of human tumor antigens: molecular definition and implications. of special interest Mol Med Today. 3:1997;342-349 Among other aspects, this review considers the techical modifications and their aims which have been implemented into the SEREX technique.
28. Türeci Ö, Sahin U, Schobert I, Koslowski M, Schmitt H, Schild HJ, Stenner F, Seitz G, Rammensee HG, Pfreundschuh M. The SSX2 gene, which is involved in the t(X, 18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-Mel-40. of outstanding interest Cancer Res. 56:1996;4766-4772 HOM-MEL-40 antigen detected in a melanoma library is encoded by the SSX-2 gene, and is the first cancer/testis antigen (i.e. a testicular antigen aberrantly expressed in human neoplasms in a lineage independent pattern) identified by SEREX. SSX2 is silenced in normal tissues, except for the testis, but is expressed in 8 out of 16 melanomas, as well as in 7 out of 36 breast cancers, 9 out of 35 colorectal carcinomas and in a lower frequency in prostate cancer and glioma. 10% of melanoma patients raise IgG responses to SSX2, SSX2 is known to participate in the t(X;18) translocation frequently found in synovial sarcoma.
29. Türeci Ö, Schmitt H, Fadle N, Pfreundschuh M, Sahin U. Molecular definition of a novel human galectin which is immunogenic in patients with Hodgkin's disease. J Biol Chem. 272:1997;6416-6422.
30. De Plaen E, Arden K, Traversari C, Gaforio JJ, Szikora JP, De Smet C, Brasseur F, van der Bruggen P, Lethe B, Lurquin C, et al. Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics. 40:1994;360-369.
31. Chen T, Scanlan J, Sahin U, Türeci Ö, Gure AO, Tsang S, Williamson S, Stockert E, Pfreundschuh M, Old LJ. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. of special interest Proc Natl Acad Sci USA. 94:1997;1914-1918 By applying SEREX to an esophageal cancer a new antigen, NY-ESO-1, expressed normally in testis with a broad spectrum of expression in different human cancers is identified. The authors introduce the term cancer/testis antigen for testicular antigens aberrently expressed in human neoplasms in a lineage independent pattern.
32. Coulie PG, Brichard V, Van Pel A, Wölfel T, Schneider J, Traversari C, De Plaen E, Lurquin C, Raunald CJ, Boon T. A new gene coding for a differentiation antigen recognized by autologous cytolytic T-lymphocytes on HLA-A2 melanomas. J Exp Med. 180:1994;36-42.
33. Schlichtholz B, Legros Y, Gillet D, Gaillard C, Marty M, Lane D, Calvo F, Soussi T. The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hotspot. Cancer Res. 52:1992;6380-6384.
34. Viola A, Lanzavecchia A. T cell activation determined by T cell receptor number and tunable thresholds. Science. 273:1996;104-106.
35. Brass N, Heckel D, Sahin U, Pfreundschuh M, Sybrecht GW, Meese E. Translation initiation factor elF-4gamma is encoded by an amplified gene and induces an immune response in squamous cell lung carcinoma. Hum Mol Genet. 6:1997;33-39.
36. Skipper JCA, Hendrickson RC, Gulden PH, Brichard V, Van Pel A, Chen Y, Shabanowitz J, Wölfel T, Slingluf CLJR, Boon T, et al. An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. of special interest J Exp Med. 183:1996;527-534 A convincing demonstration for the generation of a T cell epitope by a post-translational modification (Asn→Asp) of a tyrosinase-derived peptide in melanoma cells.
37. Chen W, Ede NJ, Jackson DC, McCluskey J, Purcell AW. CTL recognition of an altered peptide associated with asparagine bond rearrangement. Implications for immunity and vaccine design. J Immunol. 157:1996;1000-1005.
38. Baum H. Mitochondrial antigens, molecular mimicry and autoimmune disease. Biochem Biophys Acta. 24:1995;111-121.
39. Balczon R, Bao L, Zimmer WE. PCM1, a 228kD centrosome autoantigen with a distinct cell cycle distribution. J Cell Biol. 124:1994;783-793.
40. Schönberger SP, aiSercarz EE. Harnessing self reactivity in cancer immunotherapy. of special interest Semin Immunol. 8:1996;303-309 The fact that a growing list of normal self proteins are targets for CTL-responses in cancer patients is explained and the therapeutic implications for cancer are discussed.
41. Nanda NK, Sercarz EE. Induction of anti-self immunity to cure cancer. Cell. 82:1995;13-17.
42. Ono M, Yasunaga T, Miyata T, Ushikubo H. Nucleotide sequence of human endogenous retrovirus genome related to the mouse mammary tumor virus genome. J Virol. 60:1986;589-598.
43. Matzinger P. Tolerance, danger and the extended family. Annu Rev Immunol. 12:1994;991-1045.
44. Fuchs EJ, Matzinger P. Is cancer dangerous to the immune system? of special interest Semin Immunol. 8:1996;271-280 Applying their 'danger model' to neoplastic disease the authors speculate that the failure of the immune system to protect from cancer is because cancers do not appear dangerous to the immune system. As a conclusion, the authors suggest that vaccination approaches for cancer therapy should be repeatedly continued up to the complete elimination of all neoplastic cells.
45. Gaugler B, Van den Eynde B, van der Bruggen P, Romero R, Gafario JJ, De Plaen E, Lethe B, Brasseur G, Boon T. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med. 179:1994;921-930.
46. Boel P, Wildmann C, Sensei ML, Brasseur R, Renauld M, Coulie P, Boon T, van der Bruggen P. BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity. 2:1995;167-175.
47. van den Eynde, Peeters O, de Backer O, Gaugler B, Lucas S, Boon T. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med. 182:1995;689-698.
48. Heyting C, Dietrich AJJ, Moens PB, Dettmers RJ, Offenberg HH, Redeker EJW, Vink ACG. Synoptenemal complex proteins. Genome. 31:1986;81-87.
49. De Smet C, De Backer O, Faraoni I, Lurquin C, Brasseur F, Boon T. The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. of special interest Proc Natl Acad Sci USA. 93:1996;7149-7153 Using methylation analysis of DNA derived from tumor cell lines and electrophoretic mobility shift assays, it is demonstrated that methylation of a CpG island within the MAGE-1 promoter inhibits binding of transcription factors to the MAGE-1 gene. Furthermore, MAGE-1 expression is shown to be dependent on demethylation of this region which correlates with genome wide demethylation in tumors.
50. Erickson RP, Zwingman T, Ao A. Gene expression, X-inactivation, and methylation during spermatogenesis: the case of Zfa, Zfx, and Zfy in mice. Mol Reprod Dev. 35:1993;114-120.
51. Huang AY, Golumbek P, Amadzadeh M, Jaffee EW, Pardoll D, Levitsky H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science. 264:1994;961-965.
52. Robey E, Fowlkes BJ. Elective events in T cell development. Annu Rev Immunol. 12:1994;675-705.
53. Nossal GJV. Negative selection of lymphocytes. Cell. 76:1994;229-239.
54. Van Parijs L, Ibraghimov A, Abbas AK. The roles of costimulation and Fas in T cell apoptosis and peripheral tolerance. Immunity. 93:1996;951-955.
55. Hartley SB, Cooke MP, Fulcher DA, Harris AW, Cory S, Basten A, Goodnow CC. Elimination of self reactive B lymphocytes proceeds in two stages: arrested development and cell death. Cell. 72:1993;325-335.
56. Aruffo A, Farrington M, Hollenbaugh D, Li X, Milatovich A, Nonoyama S, Bajorath J, Grosmaire LS, Stenkamp R, Neubauer M. The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked Hyper-IgM syndrome. Cell. 72:1993;291-300.
57. Topalian SL, Rivoltini L, Mancini M, Markus NR, Robbins PF, Kawakami Y, Rosenberg SA. Human CD4 T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc Natl Acad Sci USA. 91:1994;9461-9465.
58. + T cell epitopes derived from the same antigen. This may provide in situ help at the tumor site for cytotoxic T cells.
59. Mattes MJ, Thomson M, Old LJ, Kenneth KO. A pigmentation-associated differentiation antigen of human melanoma defined by a precipitating antibody in human sera. Int J Cancer. 32:1983;717-721.
60. Rammensee HG, Friede T, Stefanovic S. MHC ligands and peptide motifs: first listing. Immunogenetics. 41:1995;178-228.
61. Houbiers JGA, van der Burg SH, van de Watering LMG, Tollenaar RAEM, Braund A, van de Velde CJH, Melief JM. Antibodies against p53 are associated with poor prognosis of colorectal cancer. Br J Cancer. 72:1995;632-641.
62. Coomber D, Hawkins NJ, Clark M, Meagher A, Ward RL. Characterisation and clinicopathological correlates of serum anti-p53 antibodies in breast and colon cancer. J Cancer Res Clin Oncol. 122:1996;757-762.
63. Disis ML, Cheever MA. Oncogenic proteins as tumor antigens. of special interest Curr Opin Immunol. 8:1996;637-642 This review gives a good summary of oncogenic proteins and the humoral as well as cellular immune responses raised against them.
64. Abbas AK, Murphy KM, Cher A. Functional diversity of helper lymphocytes. of special interest Nature. 383:1996;787-793 An excellent recent review summarizing the heterogeneity of T cell populations and their role in normal and pathological immune responses.
65. Lubin R, Zalcman G, Bouchet L, Tredaniel J, Legros Y, Cazals D, Hirsch A, Soussi T. Serum p53 antibodies as early markers of lung cancer. Nat Med. 1:1995;701-702.
66. Melief CJ, Offringa R, Toes RE, Kast WM. Peptide-based cancer vaccines. Curr Opin Immunol. 8:1996;651-657.
67. + patients and correlated the results with spontaneous specific cytotoxic T lymphocyte reactivity against antigenic peptides and disease progression, demonstrating an inverse relationship between antigen expression of Melan A/MART-1 and tyrosinase and the CTL response against these antigens. These studies support the hypothesis that CTL responses against melanocyte differentiation antigens may mediate the regression of antigen-positive tumors and select for antigen loss variants in vivo in cancer.
68. +, T cell clones were isolated, with some of them demonstrating a hitherto unreported restriction pattern.
69. Merinsky O, Baharav E, Shoenfeld Y, Chaitchik S, Tsigelman R, Cohen-Aloro D, Fishman O. Anti-tyrosinase antibodies in malignant melanoma. Cancer Immunol Immunother. 42:1996;297-302.
70. Kawakami Y, Eliyahu S, Delgado SH, Robbins PF, Rivoltini L, Topalian SL, Miki T, Rosenberg SA. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA. 91:1994;3515-3519.
71. Coulie PG, Brichard V, Van Pel A, Wölfel T, Schneider J, Traversari C, De Plaen E, Lurquin C, Ranauld CJ, Boon T. A new gene coding for a differentiation antigen recognized by autologous cytolytic T-lymphocytes on HLA-A2 melanomas. J Exp Med. 180:1994;36-42.
72. Hoon DS, Yuzuki D, Hayashida M, Morton DL. Melanoma patients immunized with melanoma cell vaccine induce antibody reponses to recombinant MAGE-1 antigen. J Immunol. 154:1995;730-737.
73. Fisk B, Blevins TL, Wharton JT, Ioannides CG. Identification of an immunodominant peptide of HER2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med. 181:1995;2109-2117.
74. Peoples GE, Goedegebuure PS, Smith R, Linehan DC, Yoshino I, Eberlein TJ. Breast and ovarian cancer specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci USA. 92:1995;432-436.
75. Nijman HW, Van der Burg SH, Vierboom MP, Houbiers JG, Kast WM, Melief CJ. p53, a potential target for tumor-directed T-cells. Immunol Lett. 40:1994;171-178.
76. Ropke M, Regner M, Claesson MH. T-cell mediated cytotoxicity against p53 protein derived peptides in bulk and in limiting dilution cultures of healthy donors. Scand J Immunol. 42:1995;98-103.
77. Abrams SI, Stanziale SF, Lunin SD, Zaremba S, Schlom J. Identification of overlapping epitopes in mutant ras oncogene peptides that activate CD4+ and CD8+ T cell responses. Eur J Immunol. 26:1996;435-443.
78. Fossum G, Gedde-Dahl T, Breivik J, Eriksen JA, Spurkland A, Thorsby E, Gaudemack G. p21ras-peptide specific T-cell responses in a patient with colorectal cancer CD4+ and CD8+ T cells recognize a peptide corresponding to a common mutation. Int J Cancer. 56:1994;40-45.
79. Qin H, Chen W, Takahashi M, Disis ML, Byrd DR, McCahill L, Bertram KA, Fenton RG, Peace DJ, Cheever MA. CD4+ T-cell immunity to mutated ras protein in pancreatic and colon cancer patients. Cancer Res. 55:1995;2984-2987.
80. Evans C, Bauer S, Grubert T, Brucker C, Baur S, Heeg K, Wagner H, Lipford GB. HLA-A2-restricted peripheral blood cytolytic T lymphocyte response to HPV type 16 proteins E6 and E7 from patients with neoplastic cervical lesions. Cancer Immunol Immunother. 42:1996;151-160.
81. Ressing ME, Sette A, Brandt RM, Ruppert J, Wentworth PA, Hartman M, Oseroff C, Grey HM, Melief CJ, Kast WM. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenecity studies of HLA-A0201-binding peptides. J Immunol. 154:1995;5934-5943.
82. Barnd DL, Lan MS, Metzgar RS, Finn OJ. Specific major histocompatibility complex unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proc Natl Acad Sci USA. 86:1989;7159-7163.
83. Finn OJ, Jerome KR, Henderson RA, Pecher G, Domenech N, Margarian-Blander J, Barratt-Boyes SM. MUC-1 epithellal tumor mucin-based immunity and cancer vaccines. Immunol Rev. 145:1995;61-89.